Menu

Chemical Genomics: Undruggables and the Quest for Therapeutics

The Scientist is bringing together a panel of experts to discuss chemical genomics and the advances and promises it brings to therapeutic discovery

Apr 29, 2019
The Scientist Creative Services Team

FREE Webinar

Wednesday, August 7, 2019
2:30-4:00 PM Eastern Time
Register Now

When the human genome was mapped in the early 2000s, researchers hoped that that knowing the blueprint of every disease-associated protein in the body would swiftly lead to treatments. Although mapping the human genome helped uncover various disease-associated proteins, almost two decades later, it’s clear that the complex biology of disease, combined with the endless task of screening small molecules, means that many of these targets remain undruggable. However, chemical genomics, defined as the systematic screening of small molecule libraries against various drug target families, promises to remedy this vast gap in therapeutics. Numerous high-throughput screening assays and chemical probes are employed in chemical genomics, many of which have been adapted from large-scale technologies within the pharmaceutical industry. To learn more about chemical genomics and the advances and promises it brings to therapeutic discovery, The Scientist is bringing together a panel of researchers in the chemical genomics field for this free educational webinar.

Topics to be covered:

  • Roadblocks and opportunities for protected open innovation in pharmaceutical R&D
  • Patient-led approaches to identify novel targets with chemical genomics

Register Now

Meet the Speakers:

Mel Reichman, PhD
Senior Investigator, Director, Chemical Genomics Center
CSO Small Molecule R&D
Lankenau Institute for Medical Research (LIMR)

John P. Overington, PhD
Chief Informatics Officer
Catapult Medicines Discovery, UK

September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Evaluating the Functional Potency of Immunotherapies Targeting Tumors of B Cell Origin
Download this application note to learn how the ACEA xCELLigence system can evaluate the potency of an immunotherapy against a broad spectrum of liquid tumors and monitor the destruction kinetics of liquid cancers at physiologically relevant effector:target cell ratios.
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Kinetics of Tumor Cell Killing by Tumor-Infiltrating Leukocytes
Watch this webinar to learn how Dr. Cara Haymaker and her team are assessing the reactivity of tumor-infiltrating lymphocytes and modulating the mechanisms of resistance to therapy and exploring biomarkers involved in the response.
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs